Alvogen & AZ signs sales agreement of 3 antibodies for breast and prostate cancer

Published: 2016-10-13 10:31:20

Updated: 2016-10-13 10:31:20

On the 11^th, Alvogen Korea(CEO Young-Hee Jang) announced the Korean exclusive sales agreement of AstraZeneca’s(CEO Liz Chatwin) antibodies, Zoladex(generic name: goserelin), Arimidex(generic name: anastrozole) and Casodex(generic name: bicalutamide). Thus, AstraZeneca Korea will supply the drugs, and Alvogen Korea will start marketing and sales activities in Korea from this October.

Zoladex ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.